<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590276</url>
  </required_header>
  <id_info>
    <org_study_id>P140705 -</org_study_id>
    <secondary_id>IDRCB : 2015-A00856-43</secondary_id>
    <nct_id>NCT02590276</nct_id>
  </id_info>
  <brief_title>Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>PREV-DEMALS</acronym>
  <official_title>Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project focuses on C9orf72, the most frequent genetic form of frontotemporal dementias&#xD;
      (FTD, or frontotemporal lobar degeneration, FTLD) and amyotrophic lateral sclerosis (ALS).&#xD;
      FTD is the second commonest cause of degenerative dementia in presenium after Alzheimer's&#xD;
      disease. Behavioural and cognitive impairments progressively lead to dementia. ALS produces&#xD;
      progressive muscle weakness leading to the death in 2 to 4 years. Since 2006, major&#xD;
      discoveries have linked FTLD and ALS:&#xD;
&#xD;
        1. TDP-43 aggregates in neurons and&#xD;
&#xD;
        2. C9orf72 mutations is a major genetic cause in both disorders.&#xD;
&#xD;
      Two major pathological subtypes are now defined in FTD, FTD-TDP and FTD-TAU. C9orf72&#xD;
      mutations (associated to FTD-TDP) are the most frequent genetic causes of FTD (15%), FTD-ALS&#xD;
      (65%) and ALS (40%).&#xD;
&#xD;
      FTD is difficult at an early stage; and no clinical, biological or imaging features can&#xD;
      predict the underlying pathology in living patients. Therapeutic perspectives emerged against&#xD;
      tau aggregation, progranulin deficit and C9orf72 expansion (antisense). Presymptomatic&#xD;
      carriers of genetic FTD would benefit, before onset of symptoms, from these therapeutic that&#xD;
      would delay or prevent the disease. At this step, it becomes crucial to develop markers to&#xD;
      know how many years before symptoms, does the pathological progress begin, to treat the&#xD;
      patients at the most early stage of the disease. Markers are also needed to predict the&#xD;
      pathology (FTD-TDP/FTD-tau) in patients that will be eligible for trials targeting specific&#xD;
      pathological lesion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate whether cognitive deficits, structural and functional changes can&#xD;
      be detected before symptom onset in presymptomatic mutation carrier. The main objectives of&#xD;
      the project are to identify novel cognitive, brain imaging markers and peripheral biomarkers&#xD;
      for early diagnosis of FTLD, and to follow disease progression. Methodology&#xD;
&#xD;
        1. Recruitment and evaluation of participants, neurological, behaviour and cognition&#xD;
           evaluations. One hundred participants including 20 C9orf72 patients and 80 'a-risk'&#xD;
           individuals will be recruited and evaluated by clinical partners of the project (Paris,&#xD;
           Lille, Limoges, Rouen).. 'At-risk individuals' are the first degree relatives of C9ORF72&#xD;
           patients, who have a high a risk (50%) to carry the mutation.&#xD;
&#xD;
        2. Identifying brain structural markers. Brain structural changes will be evaluated by&#xD;
           voxel-based morphometry (SPM12 software) to assess global brain atrophy and evaluation&#xD;
           of atypical shape patterns such as cortical thickness (Freesurfer software) and study of&#xD;
           the cortical sulci (BrainVISA/Morphologist software).&#xD;
&#xD;
        3. Identifying brain metabolic markers by Fluoro Deoxy DGlucose-Positron Emission&#xD;
           Tomography (FDG-PET). We will apply voxel-based methods using Statistical Parametric&#xD;
           Mapping software (SPM8) to compare different groups or analyze correlations between&#xD;
           brain metabolism and cognitive deficits.&#xD;
&#xD;
        4. Identifying peripheral biomarkers of disease onset and disease progression. We propose&#xD;
           to use RNA sequencing to study gene expression and RNA splicing alterations in&#xD;
           lymphocytes of C9ORF72 patients and 'at risk individuals'.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2015</start_date>
  <completion_date type="Actual">October 27, 2020</completion_date>
  <primary_completion_date type="Actual">October 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in behavioral assessment (20 scales)</measure>
    <time_frame>at baseline, 16 weeks and 32weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MRI morphological criteria</measure>
    <time_frame>at baseline, 16 weeks and 32weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cerebral perfusion by SPECT / PET</measure>
    <time_frame>at baseline, 16 weeks and 32weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlations between behavioral assessment, MRI morphological criteria, Cerebral perfusion and metabolism by SPECT / PET and transcriptome analysis</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Frontotemporal Lobar Degeneration</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Characterization</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>characterization</intervention_name>
    <arm_group_label>Evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Signed informed consent for genetic and clinical study&#xD;
&#xD;
          -  To be carrier of a C9ORF72 mutation - Diagnosis criteria of FTD or ALS&#xD;
&#xD;
          -  To be French-speaking&#xD;
&#xD;
          -  To be affiliated to the social security scheme&#xD;
&#xD;
          -  Absence of another intercurrent neurological pathology (vascular cerebral accident,&#xD;
             tumor, etc.....)&#xD;
&#xD;
        Inclusion criteria for asymptomatic relatives&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  To be first degree relative of a person carrying a C9ORF72 mutation OR first degree&#xD;
             relative of FTD or ALS deceased patient whose C9ORF72 mutation as been identified in&#xD;
             the family&#xD;
&#xD;
          -  Signed informed consent for genetic and clinical study&#xD;
&#xD;
          -  To be French-speaking&#xD;
&#xD;
          -  To be affiliated to the social security scheme&#xD;
&#xD;
          -  Absence of proven neurologic disorders or an intercurrent neurological pathology&#xD;
             (vascular cerebral accident, tumor, etc.....)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contra-indication to perform a brain MRI (wearing of pacemaker, cardiac valve or&#xD;
             incompatible vascular MRI surgical equipment , neurosurgery or surgery vascular&#xD;
             equipment, surgical equipment likely to concentrate the radio frequency field, intra&#xD;
             ocular or intra cerebral metal foreign body, claustrophobia, wearing a non-compliant&#xD;
             radio intrauterine device ),&#xD;
&#xD;
          -  Inability to lie one hour without moving&#xD;
&#xD;
          -  PET-FDG contra-indication&#xD;
&#xD;
          -  Breastfeeding and pregnant women&#xD;
&#xD;
          -  Human chorionic gonadotrophin (Bétâ-HCG) positive determination or Positive urine&#xD;
             pregnancy test for women of childbearing age&#xD;
&#xD;
        Exclusion criteria for related asymptomatic :&#xD;
&#xD;
          -  Clinical proven signs of FTD, language disorder, praxis disorder, mnemic, of&#xD;
             parkinson's syndrome or amyotrophic lateral sclerosis.&#xD;
&#xD;
          -  Counter-indication to perform a brain MRI (wearing of pacemaker, cardiac valve or&#xD;
             incompatible vascular MRI surgical equipment , neurosurgery or surgery vascular&#xD;
             equipment, surgical equipment likely to concentrate the radio frequency field, intra&#xD;
             ocular or intra cerebral metal foreign body, claustrophobia, wearing a non-compliant&#xD;
             radio intrauterine device )&#xD;
&#xD;
          -  Severe chronic alcoholism&#xD;
&#xD;
          -  PET-FDG contre-indication&#xD;
&#xD;
          -  Inability to lie one hour without moving&#xD;
&#xD;
          -  Bétâ-HCG positive determination or Positive urine pregnancy test for women of&#xD;
             childbearing age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LE BER Isabelle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière - Charles Foix</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>frontotemporal Dementia</keyword>
  <keyword>Amyotrophic lateral sclerosis</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>brain Imaging PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

